Genprex, Inc. (GNPX) Stock

Understand Genprex, Inc.: how it makes money

Genprex develops gene therapy candidates for cancer and diabetes, including REQORSA (GPX-001) for lung cancer, and GPX-002 for diabetes, and it makes money only if its therapies progress to later stages and eventual commercialization.

As a clinical-stage gene therapy company, Genprex's value and potential profit model depend on pipeline progress toward successful clinical development and approval, not on near-term product sales.

Business quality (Weak): Clear pipeline focus (REQORSA and preclinical GPX-002) but current results show no reported revenue and a very large negative operating margin, meaning execution risk is central.

Bull case

• Focused lead program: REQORSA (GPX-001) is the lead candidate aimed at treating non-small cell lung cancer and small cell lung cancer.
• Pipeline extension: GPX-002 is in preclinical development for diabetes, providing an additional development track beyond the lead oncology program.

Bear case

• No reported revenue in the latest quarter: For the period ending 2025-09-30, revenue is reported as 0.0B, so progress depends heavily on development rather than current sales.
• Very large negative operating margin: For the period ending 2025-09-30, operating margin is reported as -139123.2, indicating substantial operating losses.
• Clinical development uncertainty: Because the company is clinical-stage and has a preclinical diabetes candidate, outcomes for both REQORSA and GPX-002 remain uncertain.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Revelation Biosciences, Inc. (REVB)
• FibroBiologics, Inc. Common Stock (FBLG)
• GRI Bio, Inc. (GRI)
• Artelo Biosciences, Inc. (ARTL)
• 60 Degrees Pharmaceuticals, Inc. (SXTP)
• Ernexa Therapeutics Inc. (ERNA)
• Onconetix, Inc. (ONCO)
• HCW Biologics Inc. (HCWB)